We are live on
!
Find out more
SEC
Seven Eight Capital Portfolio holdings
AUM
$1.11B
1-Year Est. Return
29.48%
This Fund
S&P 500
This Quarter
Est. Return
-6.56%
1 Year Est. Return
+29.48%
3 Year Est. Return
+13.61%
5 Year Est. Return
+117.69%
10 Year Est. Return
+239.1%
AUM
$855M
AUM Growth
+$250M
(+41%)
Cap. Flow
+$327M
Cap. Flow
% of AUM
38.29%
Top 10 Holdings %
Top 10 Hldgs %
13.1%
Holding
788
New
316
Increased
155
Reduced
106
Closed
211
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$13.6M |
| 2 |
Merck
MRK
|
+$12.5M |
| 3 |
Intuitive Surgical
ISRG
|
+$11.1M |
| 4 |
DOCU
DocuSign
DOCU
|
+$10.9M |
| 5 |
Insulet
PODD
|
+$10.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nasdaq
NDAQ
|
+$7.26M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$6.86M |
| 3 |
Incyte
INCY
|
+$6.31M |
| 4 |
Fidelity National Information Services
FIS
|
+$5.73M |
| 5 |
AbbVie
ABBV
|
+$4.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.41% |
| 2 | Consumer Discretionary | 17.68% |
| 3 | Healthcare | 16.13% |
| 4 | Industrials | 12.13% |
| 5 | Financials | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
451
Tyler Technologies
TYL
$12.6B
| $369K | 0.04% |
+955
| New | +$375K |
|
452
Viatris
VTRS
$20.6B
| $368K | 0.04% |
+37,296
| New | +$388K |
|
|
PINC
453
DELISTED
Premier
PINC
| $366K | 0.04% |
17,009
-8,103
| -32% | -$202K |
|
|
DISH
454
DELISTED
DISH Network Corp.
DISH
| $365K | 0.04% |
62,206
+29,749
| +92% | +$203K |
|
455
Novartis
NVS
$294B
| $364K | 0.04% |
+3,577
| New | +$363K |
|
456
Adient
ADNT
$1.61B
| $364K | 0.04% |
+9,915
| New | +$395K |
|
457
Penske Automotive Group
PAG
$14.2B
| $363K | 0.04% |
2,172
+549
| +34% | +$91.8K |
|
458
Steel Dynamics
STLD
$38.1B
| $362K | 0.04% |
+3,372
| New | +$351K |
|
459
Molina Healthcare
MOH
$10.2B
| $359K | 0.04% |
+1,094
| New | +$344K |
|
460
Cavco Industries
CVCO
$4.52B
| $358K | 0.04% |
+1,348
| New | +$378K |
|
461
Dover
DOV
$28.3B
| $358K | 0.04% |
2,563
-36
| -1% | -$5.2K |
|
462
RenaissanceRe
RNR
$13.4B
| $356K | 0.04% |
+1,800
| New | +$346K |
|
463
Coca-Cola Consolidated
COKE
$12.3B
| $356K | 0.04% |
+5,590
| New | +$372K |
|
464
Toast
TOST
$20.2B
| $354K | 0.04% |
18,877
-6,824
| -27% | -$148K |
|
465
Cabot Corp
CBT
$4.36B
| $352K | 0.04% |
+5,086
| New | +$354K |
|
466
CBRE Group
CBRE
$43.8B
| $351K | 0.04% |
4,758
-23,529
| -83% | -$1.95M |
|
467
Option Care Health
OPCH
$3.55B
| $350K | 0.04% |
10,806
-123,667
| -92% | -$4.17M |
|
468
Packaging Corp of America
PKG
$22.8B
| $349K | 0.04% |
2,273
-2,190
| -49% | -$320K |
|
469
American States Water
AWR
$3.33B
| $349K | 0.04% |
+4,434
| New | +$378K |
|
470
Royalty Pharma
RPRX
$25.6B
| $348K | 0.04% |
12,830
-19,074
| -60% | -$567K |
|
471
Energy Fuels
UUUU
$3.11B
| $345K | 0.04% |
+41,963
| New | +$288K |
|
472
SPX Corp
SPXC
$10.8B
| $340K | 0.04% |
4,173
+291
| +7% | +$23.4K |
|
473
Q2 Holdings
QTWO
$3.97B
| $338K | 0.04% |
10,479
-27,056
| -72% | -$896K |
|
474
Tenable Holdings
TENB
$3.97B
| $338K | 0.04% |
7,536
+2,783
| +59% | +$125K |
|
475
Fastenal
FAST
$57.4B
| $337K | 0.04% |
12,342
-5,744
| -32% | -$163K |
|
Similar funds
PP
ECM
GCAC
CAM
D
GFS
FTIS
AIA
Seven Eight Capital's Q3 2023 Portfolio in Review
As of Q3 2023, Seven Eight Capital held 788 positions worth $855M, up 41% from $605M the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Seven Eight Capital deployed $327M of net new capital in Q3 2023, opening 316 new positions and adding to 155 existing holdings. Its largest new stake was Merck: 115,677 shares worth $11.9M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 22% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $6.86M trimmed.
- Seven Eight Capital's largest Q3 2023 buy was Merck: 115,677 shares worth $11.9M.
- Seven Eight Capital added most to Edwards Lifesciences in Q3 2023, an estimated $13.6M increase.
- Seven Eight Capital's biggest Q3 2023 reduction was BioMarin Pharmaceuticals, cutting an estimated $6.86M.
- Seven Eight Capital fully exited Nasdaq in Q3 2023, selling an estimated $7.26M.
- Seven Eight Capital's ten largest holdings make up 13% of its $855M portfolio in Q3 2023.
- Seven Eight Capital opened 316 new positions and closed 211 in Q3 2023.
- Seven Eight Capital's portfolio value rose 41% quarter-over-quarter to $855M.
Based on Seven Eight Capital's 13F filing for Q3 2023, filed 14 Nov 2023.